Focus on α4β2* and α6β2* nAChRs for Parkinson’s Disease Therapeutics
Read more from SRI
SRI joins a nationwide network aiming to accelerate transformative health solutions.
In this new role, Fritz will lead strategy and business development for SRI’s federal programs.
David Parekh, SRI’s CEO, has been named by the Silicon Valley Business Journal as one of the Power 100.